Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events

Archives of Internal Medicine

Volumn 162, Issue 19, 2002, Pages 2197-2202

  Weisman, Steven M ^a   Graham, David Y ^b  

^a Innovative Science Solutions   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; GASTROINTESTINAL HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS;

EID: 0037190695     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.19.2197     Document Type: Article

References (30)

1. Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation. 2000;101:1097-1101.
2. Hennekens CH, Dyken MC, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: A statement for Healthcare Professionals from the American Heart Association. Circulation. 1997;96:2751-2753.
3. Antiplatelet Triallsts' Collaboration. Collaborative overview of randomized trials of antiplatelet treatment, I: Prevention of vascular death, MI and stroke by prolonged antiplatelet agents in different categories of patients. BMJ. 1994;308: 235-246.
4. Derry S, Loke YK. Risk of gastrointestinal hemorrhage with long-term use of aspirin: Meta-analysis. BMJ. 2000;321:1183-1187.
5. Roderick J, Wilkes HC, Mead TW. The gastrointestinal toxicity of aspirin: An overview of randomized controlled trials. Br J Clin Pharmacol. 1993;35:219-226.
6. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: Final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. 63 Federal Register 56802-56819 (1998) (codified at 21 CFR Part 343).
7. Breslow NE, Day NE. Statistical methods in cancer research: IARC Workshop 25-27 May 1983. IARC Sci Publ. 1987;No. 82:1-406.
8. Chatellier G. Randomized study of n-of-1 trials versus standard practice. Rev Epidemiol Sante Publique. 1996;44:382-383.
9. Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ. 1974;1:436-440.
10. Farrell B, Godwin J, Richard S, Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
11. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827-830.
12. The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345-1349.
13. Zaijia C, Yishu X, Quanjun Y, et al. Secondary prevention of myocardial reinfarction with low dose aspirin. Chin Med Sci J. 1991;6:141-144.
14. Lewis HD Jr, and the Veterans Administration Cooperative Study Group. Unstable angina: Status of aspirin and other forms of therapy. Circulation. 1985; 72(6, pt 2):V155-V160.
15. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials. JAMA. 1998;280:1930-1935.
16. Cameron AJ. Aspirin and gastric ulcer. Mayo Clin Proc. 1975;50:565-570.
17. Dutch TIA Study Group. A comparison of two doses of aspirin (30 mg and 283 mg a day) in patients after a transient ischemic attack or minor stroke. N Engl J Med. 1991;325:1261-1266.
18. Greenberg PD, Cello JP, Rockey DC. Relationship of low-dose aspirin to GI injury and occult bleeding: A pilot study. Gastrointest Endosc. 1999;50:618-622.
19. Greenberg PD, Cello JP, Rockey DC. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am J Med. 1996;100:598-604.
20. Savon JJ, Allen ML, DiMarino AJ Jr, Hermann GA, Krum RP. Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration. Am J Gastroenterol. 1995;90:581-585.
21. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med. 1986;104:390-398.
22. Bazzoli F, De Luca L, Graham DY. Helicobacter pylori infection and the use of NSAIDs. Best Pract Res Clin Gastroenterol. 2001;15:775-785.
23. Feldman M, Cryer B, Mallat D, et al. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: A prospective placebo-controlled, double-blind, randomized trial. Am J Gastroenterol. 2001;96:1751-1757.
24. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002;16:779-786.
25. Laine L, Bombardler C, Hawkey C, et al. Influence of H. pylori and other potential risk factors on clinical gastrointestinal events in a double-blind outcome study of rofecoxib vs naproxen [abstract]. Gastroenterology. 2000;118:A4798.
26. Malfertheiner P, Megraud F, O'Morain, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-180.
27. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-973.
28. Miller DB. Secondary prevention for ischemic heart disease: Relative numbers needed to treat with different therapies. Arch Intern Med. 1997;157:2045-2052.
29. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
30. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart. 2001;85:265-271.